Finasteride and methadone use and risk of advanced hepatitis C related liver disease.

about

Sex hormone pathway gene polymorphisms are associated with risk of advanced hepatitis C-related liver disease in males Opioid use and risk of liver fibrosis in HIV/hepatitis C virus-coinfected patients in Canada.

P2860

Q34426531-70041842-9C2C-46AE-9559-FC9D158B389B Q40770942-CD94D892-5DA3-472B-95BB-34182CC5234E

P2860

Finasteride and methadone use and risk of advanced hepatitis C related liver disease.

Item

http://www.wikidata.org/entity/Q38016312

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Finasteride and methadone use and risk of advanced hepatitis C related liver disease.

@en

type

Item

label

Finasteride and methadone use and risk of advanced hepatitis C related liver disease.

@en

prefLabel

Finasteride and methadone use and risk of advanced hepatitis C related liver disease.

@en

P1476

Finasteride and methadone use and risk of advanced hepatitis C related liver disease.

@en

P2093

Ali Hashmi

http://www.w3.org/2001/XMLSchema#string

David J Ramsey

http://www.w3.org/2001/XMLSchema#string

Donna L White

http://www.w3.org/2001/XMLSchema#string

Hashem B El-Serag

http://www.w3.org/2001/XMLSchema#string

Jill Kuzniarek

http://www.w3.org/2001/XMLSchema#string

Shahriar Tavakoli-Tabasi

http://www.w3.org/2001/XMLSchema#string

P2860

Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data

Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis

Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase).

Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.

EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.

Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia.

Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.

Hypogonadism in men receiving methadone and buprenorphine maintenance treatment.

A cohort study of serum testosterone and hepatocellular carcinoma in Shanghai, China.

P2888

s10620-012-2231-3

P304

3004-3010

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10620-012-2231-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1043500001

http://www.w3.org/2001/XMLSchema#string

P698

22669204

http://www.w3.org/2001/XMLSchema#string

Finasteride and methadone use and risk of advanced hepatitis C related liver disease.

about

P2860

P2860

Finasteride and methadone use and risk of advanced hepatitis C related liver disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698